Might life-threatening acute pulmonary edema occur after using recombinant tissue plasminogen activator? A case report.


Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
09 Sep 2021
Historique:
received: 21 09 2020
accepted: 27 08 2021
entrez: 10 9 2021
pubmed: 11 9 2021
medline: 16 10 2021
Statut: epublish

Résumé

Recombinant tissue plasminogen activator (rt-pa) is the first-line drug for the treatment of acute ischemic stroke, and can lead to some complications.There were rare reports of death due to acute pulmonary edema during rt-pa thrombolysis treatment. This study reports a 30-year-old man was diagnosed with acute ischemic stroke and underwent rt-pa thrombolytic therapy. Finally he died despite active rescue. The autopsy revealed that he died of acute pulmonary edema. This case suggests that it is necessary to pay close attention to the changes of vital signs during thrombolysis and be aware of possibility of pulmonary edema during thrombolysis.

Sections du résumé

BACKGROUND BACKGROUND
Recombinant tissue plasminogen activator (rt-pa) is the first-line drug for the treatment of acute ischemic stroke, and can lead to some complications.There were rare reports of death due to acute pulmonary edema during rt-pa thrombolysis treatment.
CASE PRESENTATION METHODS
This study reports a 30-year-old man was diagnosed with acute ischemic stroke and underwent rt-pa thrombolytic therapy. Finally he died despite active rescue.
CONCLUSIONS CONCLUSIONS
The autopsy revealed that he died of acute pulmonary edema. This case suggests that it is necessary to pay close attention to the changes of vital signs during thrombolysis and be aware of possibility of pulmonary edema during thrombolysis.

Identifiants

pubmed: 34503474
doi: 10.1186/s12883-021-02371-w
pii: 10.1186/s12883-021-02371-w
pmc: PMC8427873
doi:

Substances chimiques

Fibrinolytic Agents 0
Recombinant Proteins 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

346

Subventions

Organisme : Guangzhou Sci-Tech Project
ID : 201804010307

Informations de copyright

© 2021. The Author(s).

Références

N Engl J Med. 2005 Dec 29;353(26):2788-96
pubmed: 16382065
Am J Emerg Med. 2012 Jan;30(1):253.e1-2
pubmed: 21109385
Cell Mol Life Sci. 2019 Apr;76(8):1489-1506
pubmed: 30656378
Int J Gen Med. 2012;5:743-51
pubmed: 23049267
Iran J Neurol. 2013;12(3):114-6
pubmed: 24250917
Am J Emerg Med. 2014 Jan;32(1):113.e3-5
pubmed: 24091200
Nat Rev Immunol. 2010 Jun;10(6):440-52
pubmed: 20498670

Auteurs

Xue-Bing Chen (XB)

School of Forensic Medicine, Southern Medical University, 510515, Guangzhou, China.

Dong Qu (D)

School of Forensic Medicine, Southern Medical University, 510515, Guangzhou, China.
Institute of Legal Medicine, Hannover Medical School, 30625, Hannover, Germany.

Qing Zhang (Q)

Nan Fang Hospital Pharmacy Department of the Southern Medical University, 510515, Guangzhou, China.

Xia Yue (X)

School of Forensic Medicine, Southern Medical University, 510515, Guangzhou, China.

Dong-Fang Qiao (DF)

School of Forensic Medicine, Southern Medical University, 510515, Guangzhou, China. qiaodf@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH